BioCentury
ARTICLE | Clinical News

Xiaflex regulatory update

November 23, 2015 8:00 AM UTC

The European Commission approved a label expansion for Xiapex collagenase clostridium histolyticum from Swedish Orphan to treat 2 palpable cords concurrently in adults with Dupuytren’s contracture, which affects joints in the hand. The injectable form of collagenase was approved to treat 1 cord during a doctor’s visit. It is also approved in the EU to treat Peyronie’s disease with a palpable plaque and curvature deformity of 30 degrees. ...